Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Clinical trial for new cataract surgery technology ➤ Topline results from Phase 2 trial investigating treatment for persistent corneal epithelial defect ➤ Update on sustained-release glaucoma implant and Glaukos cornea programs ➤ First patient enrolled in Phase 3 trial for presbyopia drop ➤ ASCRS news and events
➤ FDA approves NDA for IOP-lowering drug ➤ NDA submitted for presbyopia drop ➤ IND accepted for investigational treatment of persistent corneal epithelial defect ➤ Topline results from Phase 2 study of novel sedation drug for cataract surgery ➤ First patient enrolled in Phase 3 trial for investigational TED therapy ➤ Complimentary access to video journal ➤ ASCRS news and events
Constance Okeke, MD, is a wife, mother, surgeon, researcher, assistant professor, consultant, and a soon-to-be two-time book author. EyeWorld caught up with her to learn more about her latest written endeavor and get some insights on what the process of book writing is like for a busy ophthalmologist.
Glaucoma Editor Nathan Radcliffe, MD, spoke about EyeWorld’s approach to glaucoma management and introduced the new Glaucoma Editor, Manjool Shah, MD.
While glaucoma specialists are likely familiar with MicroPulse Laser Therapy (Iridex) as a non-incisional, non-pharmaceutical glaucoma therapy, two physicians called it an “ace up your sleeve” and one that can be adopted by any surgeon who treats glaucoma patients.
➤ FDA accepts NDA for pupil dilation spray ➤ NDA for new glaucoma drug accepted ➤ PMA application submitted to FDA for new IOL ➤ Data report: 12-month efficacy seen from single mechanical MGD treatment ➤ Acquisition of company developing drugs for rare ophthalmic diseases ➤ ASCRS news and events
Two physicians shared their reasons for and experiences with combining MIGS procedures.
When the term MIGS was first coined more than a decade ago, there were only a few options in the space. Since then, the MIGS space has grown significantly with many options addressing the same outflow pathway. As such, it might be time to start talking about MIGS in terms of procedural categories.
Innovation is changing the philosophy of glaucoma treatment from a drop-dependent approach to an interventional, procedure-based approach, according to Savak Teymoorian, MD. Where he’s found the philosophy shift toward acceptance of interventional glaucoma among patients has been with Durysta (bimatoprost intracameral implant, Allergan).
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events